Current Evidence for the Management of Inflammatory Bowel Diseases Using Fecal Microbiota Transplantation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jeon, Seong Ran | - |
dc.contributor.author | Chai, Jocelyn | - |
dc.contributor.author | Kim, Christiana | - |
dc.contributor.author | Lee, Christine H. | - |
dc.date.accessioned | 2021-08-11T11:44:09Z | - |
dc.date.available | 2021-08-11T11:44:09Z | - |
dc.date.issued | 2018-08 | - |
dc.identifier.issn | 1523-3847 | - |
dc.identifier.issn | 1534-3146 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/5761 | - |
dc.description.abstract | Purpose of Review Fecal microbiota transplantation (FMT) has been investigated as a potential treatment for inflammatory bowel disease (IBD). This review examines current evidence around the efficacy and safety of FMT for patients with IBD. Recent Findings Randomized controlled trials (RCTs) and meta-analyses have suggested that FMT may facilitate clinical and endoscopic remission in patients with active ulcerative colitis (UC). Although the evidence for FMT in Crohn's disease (CD) is more limited, positive outcomes have been observed in small cohort studies. Most adverse events (AEs) were mild and included transient gastrointestinal symptoms. Serious adverse events (SAEs) did not differ significantly between the FMT and control groups, and a marginal increased rate of IBD flares following FMT was observed. Microbiota analysis following FMT showed increased intestinal bacterial diversity and a shift towards the donor microbial profile in recipients' stools. Summary FMT for patients with IBD is promising as RCTs have shown the benefit of FMT for UC, although the efficacy of FMT for CD is less clear. Further large and well-designed trials are necessary to resolve critical issues such as the donor selection, the ideal route of administration, duration, frequency of FMT, and the long-term sustained efficacy and safety. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Current Science Inc. | - |
dc.title | Current Evidence for the Management of Inflammatory Bowel Diseases Using Fecal Microbiota Transplantation | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1007/s11908-018-0627-8 | - |
dc.identifier.scopusid | 2-s2.0-85047544008 | - |
dc.identifier.wosid | 000433292500001 | - |
dc.identifier.bibliographicCitation | Current Infectious Disease Reports, v.20, no.8 | - |
dc.citation.title | Current Infectious Disease Reports | - |
dc.citation.volume | 20 | - |
dc.citation.number | 8 | - |
dc.type.docType | Review | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Infectious Diseases | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.subject.keywordPlus | CLOSTRIDIUM-DIFFICILE INFECTION | - |
dc.subject.keywordPlus | ACTIVE ULCERATIVE-COLITIS | - |
dc.subject.keywordPlus | 2ND KOREAN GUIDELINES | - |
dc.subject.keywordPlus | INTESTINAL MICROBIOTA | - |
dc.subject.keywordPlus | RECURRENT | - |
dc.subject.keywordPlus | PATHOGENESIS | - |
dc.subject.keywordPlus | REMISSION | - |
dc.subject.keywordPlus | BACTERIA | - |
dc.subject.keywordPlus | INTENSITY | - |
dc.subject.keywordPlus | DYSBIOSIS | - |
dc.subject.keywordAuthor | Fecalmicrobiota transplantation | - |
dc.subject.keywordAuthor | Inflammatory bowel disease | - |
dc.subject.keywordAuthor | Ulcerative colitis | - |
dc.subject.keywordAuthor | Crohn's disease | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.